Get the Stockscreener App
2.05
12.02%
0.22
After Hours:
2.04
-0.010
-0.49%
Caribou Biosciences Inc stock is traded at $2.05, with a volume of 2.96M.
It is up +12.02% in the last 24 hours and up +60.16% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$1.83
Open:
$1.87
24h Volume:
2.96M
Relative Volume:
2.12
Market Cap:
$190.66M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-1.4041
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
+25.77%
1M Performance:
+60.16%
6M Performance:
+33.99%
1Y Performance:
-14.58%
1-Day Range:
$1.835
$2.13
1-Week Range:
$1.605
$2.13
52-Week Range:
$0.66
$2.9995
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
2.05 | 151.60M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
What analysts say about Caribou Biosciences Inc. stockRapid return acceleration - Jammu Links News
Why Caribou Biosciences Inc. stock is on top investor watchlistsFast Gains With Reduced Risk - Newser
Citi reiterates Buy rating on Caribou Biosciences stock ahead of key data - Investing.com Australia
Caribou Biosciences: Key Data Updates Coming, But I'm Concerned About Near-Term Volatility - Seeking Alpha
Investors Can Still File Late Claims in Caribou Bioscience Settlement — Here’s How to Get Your Share - TradingView
Rachel Haurwitz - Forbes
Why Caribou Biosciences Inc. stock attracts strong analyst attentionRisk Adjusted Stock Signals - Newser
How Caribou Biosciences Inc. stock performs during market volatilityTriple Return With Stability - Newser
What makes Caribou Biosciences Inc. stock price move sharplyVerified Return Tips - Newser
Caribou Biosciences(CRBU) soars 9.38% on FDA clearance, institutional interest - AInvest
Caribou Biosciences shares rise 1.88% in premarket after being listed as one of four stocks poised to ride the 2025 biotech growth wave. - AInvest
Biotech Sector Shows Promising Growth with Key Players Leading Innovation - citybuzz -
Caribou Biosciences (CRBU) Is Paying a $3.9M Settlement to Investors — Here’s How to Get Your Share - TradingView
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. LawsuitCRBU - ACCESS Newswire
Caribou Biosciences Regains Nasdaq Compliance, Maintains Minimum Closing Bid Price - AInvest
Caribou Biosciences regains Nasdaq compliance with $1 minimum bid By Investing.com - Investing.com Canada
Discovering RF Industries And 2 Other Promising Penny Stocks - simplywall.st
Caribou Biosciences Announces Director Elections and Auditor Confirmation - AInvest
Caribou Biosciences Confirms Director Elections and Auditor - TipRanks
Analysts Offer Predictions for CRBU FY2026 Earnings - Defense World
Caribou Biosciences (NASDAQ:CRBU) versus AlloVir (NASDAQ:ALVR) Critical Contrast - Defense World
Public Employees Retirement System of Ohio Takes $222,000 Position in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Nuveen Asset Management LLC Acquires 63,096 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCRBU - ACCESS Newswire
Millennium Management LLC Has $1.37 Million Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Ameriprise Financial Inc. Purchases New Position in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
CRISPR Market Research and Competitive Landscape Report 2025Global Forecast to 2030: Rising Adoption in Research and Therapy Drives Growth with Thermo Fisher Scientific and Merck Leading - GlobeNewswire
Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Acquired by Two Sigma Investments LP - Defense World
Bank of America Corp DE Sells 2,800,953 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences, Inc. (NASDAQ:CRBU) Holdings Lowered by Jane Street Group LLC - Defense World
Northern Trust Corp Boosts Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Caribou Biosciences CEO Fireside Chat: Latest CRISPR Innovations at Jefferies Conference - Stock Titan
Caribou Biosciences’ SWOT analysis: biotech stock faces pivotal moment By Investing.com - Investing.com South Africa
Caribou Biosciences’ SWOT analysis: biotech stock faces pivotal moment - Investing.com
Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Anti-CD152 Antibody Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences - Barchart.com
Shareholders that lost money on Caribou Biosciences, Inc.(CRBU) should contact Levi & Korsinsky about pending Class ActionCRBU - ACCESS Newswire
Crispr Therapeutics Products 2025: Therapies, MOA Insights, - openPR.com
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates - MSN
Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $9.33 - Defense World
Cantor Fitzgerald Analysts Lower Earnings Estimates for CRBU - Defense World
Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know - MSN
Dimensional Fund Advisors LP Sells 321,867 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Barclays PLC Grows Stock Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):